Please assess the completion status of the following clinical trial:

Trial Title: HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years of age with histologically proven squamous cell carcinoma of the larynx.~* Stage T1-2N1-2c/T3-4N0-2c disease, as defined by American Joint Committee on Cancer (AJCC) criteria.~* ECOG (Zubrod) performance status 0-2.~* Must be functionally and technically fit for partial laryngectomy.~* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.~* Ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* Patients who have undergone resection of primary disease.~* Patients who have received induction chemotherapy for their cancer diagnosis.~* Patients who have undergone a diverting tracheostomy which is either a) traversing directly through tumor, b) has been placed for true airway insufficiency. Patients with a tracheostomy placed preemptively for impending airway compromise remain eligible for enrollment.~* Prior cancer diagnosis, except appropriately treated localized epithelial skin cancer or cervical cancer.~* Prior radiation therapy to the head and neck region.~* Women of childbearing potential (a woman of child-bearing potential is a reproductively mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months \[i.e., who has had menses at any time in the preceding 24 consecutive months\]) and male participants must practice effective contraception (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.~* Patients unable or unwilling to give written, informed consent.~* Severe, active co-morbidity, defined as follows:~  1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.~ 2. Transmural myocardial infarction within the last 6 months.~ 3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.~ 4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration.~ 5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.~ 6. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. Protocol-specific requirements may also exclude immuno-compromised patients.~ 7. History of treatment with potent immunosuppressive drugs for such conditions as post organ transplant, severe rheumatoid arthritis, etc. within the past 6 months.~* Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants~* Evidence of metastatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Radiation (Type: EXPERIMENTAL): Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.

Based on this trial design, predict the completion outcome and termination type (if applicable).